GlassScriptPhysician profile
Gregory K Hutteger
NPI 1992744833
$2,554.93
in general payments reported to CMS, 2019-2025
34 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $162 · 2021: $398 · 2022: $455 · 2023: $391 · 2024: $294 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $743.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $337.75 | 2021-2025 | |
| Amgen INC. | $263.41 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $170.81 | 2019-2025 | |
| Gilead Sciences, INC. | $116.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $99.30 | 2019-2025 | |
| Lilly USA, LLC | $75.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $69.70 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.89 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.03 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $51.53 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $46.64 | 2025 | Gemtesa |
| Boston Scientific Corporation | $39.29 | 2022-2024 | Watchman Flx |
| Astellas Pharma US INC | $37.06 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $31.11 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $30.30 | 2021-2022 | |
| Medtronic, INC. | $29.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.04 | 2021-2022 | |
| Pulmonx Corporation | $24.04 | 2022 | |
| Abbott Laboratories | $23.94 | 2024 | Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $20.81 | 2025 | Opsumit, Uptravi |
| Antares Pharma, INC. | $18.90 | 2021 | |
| Dynavax Technologies Corporation | $17.91 | 2025 | Heplisav-B |
| Jazz Pharmaceuticals INC. | $17.76 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.40 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.33 | 2021 | |
| Exact Sciences Corporation | $15.40 | 2024 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $14.96 | 2022 | |
| Amarin Pharma, INC. | $14.83 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.04 | 2021 | |
| Daiichi Sankyo INC. | $12.79 | 2020 | |
| Mannkind Corporation | $12.18 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.46 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Hutteger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.